Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 1,141–1,150 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 1141

    Medicine slug
    oxaliplatin
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    24
    Source count
    24
    Agreement rate
    1
    Recorded readings

    1. 440 L

      Numeric value
      440
      Unit
      L
      Source records
      24

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 24 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:21a2bb1d-d91d-4f99-97dd-cc67fe99a090 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0799e39-7b1e-430a-b159-062b39521001 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were Cmax of 0.814 mcg/mL and volume of distribution of 440 L.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b805925-beb1-2bac-e054-00144ff88e88 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of Oxaliplatin injection at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a6f89dc3-a594-4b5b-8728-272e20c1ecb5 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were Cmaxof 0.814 mcg/mL and volume of distribution of 440 L.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7e38318e-c569-4ad4-8f10-a235f30444d1 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11377169-7986-45b1-8298-6f0533efa3c3 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e9e47f3c-9acc-44f5-b0bd-d26fe9d35d64 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin for injection at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b6083405-9b45-4d2c-e053-2995a90ad9ef (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin injection at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafilterable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee5a5a1d-63f6-4d5a-901b-65be45ec6610 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin injection at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86f6c19d-30d1-42e3-8d46-5e3f45776e85 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f299b2d2-86ed-4fb8-822e-65455a0bb75a (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:873fa936-157a-4f85-bc70-5df31d71d122 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ac38523-480b-4c0f-97a1-7dfa1432923c (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin injection at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee2e0da9-5ae7-405b-8dd1-635be72bc439 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fad0f147-6595-4412-87a7-2afca0192a96 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were Cmaxof 0.814 mcg/mL and volume of distribution of 440 L.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7dc8dfb1-dec8-43b3-b2ea-05eac054b2c6 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d6178bc6-9dae-413f-8f47-de75d576c5b8 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        Pharmacokinetic parameters obtained after a single 2-hour intravenous infusion of oxaliplatin for injection at a dose of 85 mg/m 2 expressed as ultrafilterable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:33d4f4b4-bb4e-46af-9e89-df20154436d0 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin injection at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29a5d098-bfa7-4a65-bb4f-5daa1fef1c2f (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1bb4febd-0ed4-48c9-ba2a-e22183a2143f (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e51a62ba-d163-4c57-835c-8c86cf097e40 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of Oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ab162009-6f84-4d56-ab56-5e84409ec814 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bb180ec5-1f75-43c1-9f63-c0657af2ca5f (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin injection at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da0e8523-609a-4326-96b1-d7de78662d91 (opens source in a new tab)

        Oxaliplatin label

        Version not recorded · Effective date not recorded

        After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2 , pharmacokinetic parameters expressed as ultrafiltrable platinum were C max of 0.814 mcg/mL and volume of distribution of 440 L.

  2. Projected row 1142

    Medicine slug
    oxaprozin
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    10
    Source count
    10
    Agreement rate
    1
    Recorded readings

    1. 22 hours

      Numeric value
      22
      Unit
      hours
      Source records
      10

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 10 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da457b34-ca08-60df-045b-1ae80d2f7e71 (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Upon chronic dosing, the accumulation half-life is approximately 22 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c157016e-0777-4ad7-89b8-487c47bb74cb (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Upon chronic dosing, the accumulation half-life is approximately 22 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:450f5941-7f10-42fe-e063-6394a90a4803 (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Upon chronic dosing, the accumulation half-life is approximately 22 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3fbea8c-bc0d-4dcd-a14e-a4575dceeea6 (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Upon chronic dosing, the accumulation half-life is approximately 22 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e881dca6-004e-1c3e-e053-2a95a90a02ab (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Upon chronic dosing, the accumulation half-life is approximately 22 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:918127f0-9f2a-4edf-a2f7-07c01aa52bb5 (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Upon chronic dosing, the accumulation half-life is approximately 22 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:284ce161-0a4a-8999-e063-6394a90aa60a (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Upon chronic dosing, the accumulation half-life is approximately 22 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9b0ca6c-4c53-4f6e-918b-02a8c472a194 (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Upon chronic dosing, the accumulation half-life is approximately 22 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:db349233-9f09-471c-aeee-f91338d2ffe9 (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Upon chronic dosing, the accumulation half-life is approximately 22 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dcb85e40-3427-4e56-910d-c1b07bb5c0fa (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Upon chronic dosing, the accumulation half-life is approximately 22 hours.

  3. Projected row 1143

    Medicine slug
    oxaprozin
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    10
    Source count
    10
    Agreement rate
    1
    Recorded readings

    1. 11 to 17 L

      Numeric value
      11
      Unit
      L
      Source records
      10

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 10 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da457b34-ca08-60df-045b-1ae80d2f7e71 (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution (Vd/F) of total oxaprozin is approximately 11 to 17 L/70 kg.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c157016e-0777-4ad7-89b8-487c47bb74cb (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution (Vd/F) of total oxaprozin is approximately 11 to 17 L/70 kg.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:450f5941-7f10-42fe-e063-6394a90a4803 (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution (Vd/F) of total oxaprozin is approximately 11 to 17 L/70 kg.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3fbea8c-bc0d-4dcd-a14e-a4575dceeea6 (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution (Vd/F) of total oxaprozin is approximately 11 to 17 L/70 kg.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e881dca6-004e-1c3e-e053-2a95a90a02ab (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution (Vd/F) of total oxaprozin is approximately 11 to 17 L/70 kg.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:918127f0-9f2a-4edf-a2f7-07c01aa52bb5 (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution (Vd/F) of total oxaprozin is approximately 11 to 17 L/70 kg.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:284ce161-0a4a-8999-e063-6394a90aa60a (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution (Vd/F) of total oxaprozin is approximately 11 to 17 L/70 kg.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9b0ca6c-4c53-4f6e-918b-02a8c472a194 (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution (Vd/F) of total oxaprozin is approximately 11 to 17 L/70 kg.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:db349233-9f09-471c-aeee-f91338d2ffe9 (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution (Vd/F) of total oxaprozin is approximately 11 to 17 L/70 kg.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dcb85e40-3427-4e56-910d-c1b07bb5c0fa (opens source in a new tab)

        Oxaprozin label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution (Vd/F) of total oxaprozin is approximately 11 to 17 L/70 kg.

  4. Projected row 1144

    Medicine slug
    oxazepam
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    5
    Source count
    5
    Agreement rate
    1
    Recorded readings

    1. 8.2 hours

      Numeric value
      8.2
      Unit
      hours
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f1e50d01-f529-4894-97d4-0af680a8b461 (opens source in a new tab)

        Oxazepam label

        Version not recorded · Effective date not recorded

        The mean elimination half-life for oxazepam was approximately 8.2 hours (range 5.7 to 10.9 hours).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bda8bc70-3328-46f2-89d5-7ef7a061b418 (opens source in a new tab)

        Oxazepam label

        Version not recorded · Effective date not recorded

        The mean elimination half-life for oxazepam was approximately 8.2 hours (range 5.7 to 10.9 hours).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a0d5a4c1-ec79-42e6-8e8f-ae4d144edb43 (opens source in a new tab)

        Oxazepam label

        Version not recorded · Effective date not recorded

        The mean elimination half-life for oxazepam was approximately 8.2 hours (range 5.7 to 10.9 hours).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03440821-831c-4085-98f9-faa88e98c503 (opens source in a new tab)

        Oxazepam label

        Version not recorded · Effective date not recorded

        The mean elimination half-life for oxazepam was approximately 8.2 hours (range 5.7 to 10.9 hours).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:67f821fa-5663-4d69-82c9-5ee13a09f324 (opens source in a new tab)

        Oxazepam label

        Version not recorded · Effective date not recorded

        The mean elimination half-life for oxazepam was approximately 8.2 hours (range 5.7 to 10.9 hours).

  5. Projected row 1145

    Medicine slug
    oxcarbazepine
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    76
    Source count
    69
    Agreement rate
    1
    Recorded readings

    1. 19 hours

      Numeric value
      19
      Unit
      hours
      Source records
      69

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 69 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ebcb0e5-1c93-4b3f-8749-6835c56afce5 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8edaa2b-3bab-4030-a4e3-0c77f7655731 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:21b0cc84-b64a-75de-e063-6294a90a9dd0 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6)].
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a20e4a95-8ee1-e702-003e-e353ec1ee133 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When immediate-release oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a two-fold increase in AUC.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:962098cc-2d84-4723-a296-b110f1fd659e (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 )].
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c2affa00-1d57-4d85-8db3-745191b4714d (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance less than 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51008af2-39ac-546c-e063-6294a90a758f (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 ) ].
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e23d8a74-b47b-462a-b09c-90bdd58a032e (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ab4c1f36-82fa-40a2-a31a-227875d0f382 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6)] .
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38694974-3dc6-42b5-bdf9-b5354e35330b (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f36f519-c30c-4929-afa0-9844dc531e3f (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine oral suspension is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 )].
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2515391e-3a88-4226-92e5-f641c8409fe5 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ] .
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec033897-21b4-4d08-83de-042783e89251 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 ) ] .
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50873ef7-3deb-7386-e063-6394a90a9c19 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 ) ].
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0f9df3f-280e-4394-8d7e-ad04803b2635 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03bec567-a9c3-4d82-9679-fec5324d0df6 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbea45c2-e166-b557-e053-2995a90a7643 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6)].
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:95867dcd-fd0e-4570-987b-d35939f7d7d1 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d947e9b1-2a15-4048-bb4e-fe56b6851848 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When immediate-release oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a two-fold increase in AUC.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a18f591b-587e-4769-8ac2-9cfba0b82526 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:188a48ad-c412-416a-b15b-de5f232740a2 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 )].
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e0f8d9f-7659-4524-8f93-6200314356c8 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8841174a-9f4b-424f-a50d-01478f2aeb29 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ] .
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:512ab25c-ea79-1e59-e063-6294a90ae9a0 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 )].
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:255f64ba-7667-48e6-8599-3b598bf6f4e9 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:62dfed1d-4c5b-446d-97b3-bad9c33959ff (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ] .
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e156339c-f79e-4a20-b9da-f50bea948213 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Error! Hyperlink reference not valid. and ].
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3fb47782-3dfc-458c-92a6-493de1207c0e (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 )].
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ecd5eef-46f4-407f-9b63-ba65adb3eced (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7718f8b-63e2-40b9-b519-e687cfc2cacf (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 )].
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a2032bcc-2da5-45e5-aa3f-ddbf50909df8 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 ) ].
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa610e56-1d1d-11e1-8bc2-0800200c9a66 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When immediate-release oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a two-fold increase in AUC.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c42b2cb2-8b45-488b-bf63-81909a1f06cb (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 )].
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5048dc87-2d89-434d-be51-4a97b0ce0601 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd8da0e9-d69b-7587-e053-6294a90a33c0 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 )].
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f15c889-4386-850b-e063-6294a90a8dbf (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ] .
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1b6a698-f7d9-4adb-9e38-b63e7a85e2b3 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ] .
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:567c0777-9bc5-45a9-ba25-959dd76d0e05 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b571ee0f-3c2a-4c55-9c2b-e00014e2ec7a (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54fb494e-bce4-442d-954a-757f9851e81e (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:148b90ba-236a-47cc-b171-22dd7f8f8e0a (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ] .
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23137a89-cbd0-4a5f-8220-f26b7ba54330 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 )].
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78f196d4-110e-45b1-813a-725f52c1a4eb (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d3c7a3b8-b9a2-4a5f-98b3-0ed02eca3433 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1746d95f-c529-45ba-a520-0c135e8edda8 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1176d5f5-3447-4925-aed8-1a1cb4b5989d (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ] .
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b9db5c45-8b51-449b-b4af-1a235c08f189 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85a9bdee-4d10-4097-ae3d-0bf8d844a11b (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a90cd1f1-5258-4b0e-92fd-c4cebe47772b (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 ) ].
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9f5d17e4-ca68-48e2-9e87-d3ab1c59aa93 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 )].
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0abe9478-4084-286d-e063-6294a90a9ba7 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 )].
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe49a773-562c-4da6-96b7-bba52f4d61e2 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 )].
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1c713b59-a628-42e6-b166-ae71c3913284 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 ) ].
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6d2a6cac-f16b-4e6c-8f75-3afffb0a0f3b (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When TRILEPTAL is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2. 7 ) and Use in Specific Populations (8.6) ].
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:636fc847-b3d2-4255-a959-d75499fdb198 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ] .
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ffc8d10c-0049-4fe5-beb8-79cc6a197ede (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:867eaf99-3e31-4f75-bfae-2898804d956d (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6)] .
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a14b5756-4fd1-4ba7-bc23-e1fa9212a148 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6)] .
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:70798ca9-0eda-49c0-8a7c-b775b6ae3d69 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When immediate-release oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a two-fold increase in AUC.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20d826cd-fa4a-4570-9e10-9d7d10fb725b (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 )].
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:682a1210-b26e-426e-8ffe-d25d91bdd608 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:433d9d03-a36e-42c6-8e4d-f333ed60e45a (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration ( 2.7 ) and Use in Specific Populations ( 8.6 )].
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d5ba8a3-d1ea-4d5b-aafd-3a7ba2d4746c (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepineis administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ] .
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47b92168-6832-1e0b-e063-6394a90a079a (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6)] .
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:244f9a68-5ab4-46b8-a01f-538572fd3c5f (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e46d4654-76bc-4c33-ac2b-e89ae11b7697 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ] .
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fcf5044a-8cfd-47d5-9f47-8f6674843c24 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance < 30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1d54def-057d-4608-bc8f-1d967ac3ec91 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        When oxcarbazepine tablets is administered as a single 300 mg dose in renally-impaired patients (creatinine clearance <30 mL/min), the elimination half-life of MHD is prolonged to 19 hours, with a 2-fold increase in AUC [ see Dosage and Administration (2.7) and Use in Specific Populations (8.6) ].

  6. Projected row 1146

    Medicine slug
    oxcarbazepine
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    76
    Source count
    39
    Agreement rate
    1
    Recorded readings

    1. 6 hours

      Numeric value
      6
      Unit
      hours
      Source records
      39

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 39 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:962098cc-2d84-4723-a296-b110f1fd659e (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c2affa00-1d57-4d85-8db3-745191b4714d (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87f53c04-075c-4d09-925a-0faeaa14f3f9 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e23d8a74-b47b-462a-b09c-90bdd58a032e (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f36f519-c30c-4929-afa0-9844dc531e3f (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2515391e-3a88-4226-92e5-f641c8409fe5 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec033897-21b4-4d08-83de-042783e89251 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0f9df3f-280e-4394-8d7e-ad04803b2635 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03bec567-a9c3-4d82-9679-fec5324d0df6 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a18f591b-587e-4769-8ac2-9cfba0b82526 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:188a48ad-c412-416a-b15b-de5f232740a2 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e0f8d9f-7659-4524-8f93-6200314356c8 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8841174a-9f4b-424f-a50d-01478f2aeb29 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of TRILEPTAL oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:512ab25c-ea79-1e59-e063-6294a90ae9a0 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:62dfed1d-4c5b-446d-97b3-bad9c33959ff (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d3684d55-0564-4849-bdf6-b91f22a3e28c (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ef6a941-a017-40f2-a50a-ab66c43b3347 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3fb47782-3dfc-458c-92a6-493de1207c0e (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7718f8b-63e2-40b9-b519-e687cfc2cacf (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c42b2cb2-8b45-488b-bf63-81909a1f06cb (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5048dc87-2d89-434d-be51-4a97b0ce0601 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd8da0e9-d69b-7587-e053-6294a90a33c0 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:148b90ba-236a-47cc-b171-22dd7f8f8e0a (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23137a89-cbd0-4a5f-8220-f26b7ba54330 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1746d95f-c529-45ba-a520-0c135e8edda8 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7be73d22-f87b-4459-a91c-37c1e34db230 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9f5d17e4-ca68-48e2-9e87-d3ab1c59aa93 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0abe9478-4084-286d-e063-6294a90a9ba7 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe49a773-562c-4da6-96b7-bba52f4d61e2 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e74bb389-8426-4ffc-a14b-a5990de6d0d4 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of TRILEPTAL oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:62ab716b-f05f-454d-95b3-1a382cdf7226 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:636fc847-b3d2-4255-a959-d75499fdb198 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:867eaf99-3e31-4f75-bfae-2898804d956d (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a14b5756-4fd1-4ba7-bc23-e1fa9212a148 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20d826cd-fa4a-4570-9e10-9d7d10fb725b (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:433d9d03-a36e-42c6-8e4d-f333ed60e45a (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47b92168-6832-1e0b-e063-6394a90a079a (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of oxcarbazepine oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e46d4654-76bc-4c33-ac2b-e89ae11b7697 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        After single-dose administration of TRILEPTAL oral suspension to healthy male volunteers under fasted conditions, the median t max was 6 hours.

  7. Projected row 1147

    Medicine slug
    oxcarbazepine
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    76
    Source count
    76
    Agreement rate
    1
    Recorded readings

    1. 49 L

      Numeric value
      49
      Unit
      L
      Source records
      76

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 76 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ebcb0e5-1c93-4b3f-8749-6835c56afce5 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8edaa2b-3bab-4030-a4e3-0c77f7655731 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:21b0cc84-b64a-75de-e063-6294a90a9dd0 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a20e4a95-8ee1-e702-003e-e353ec1ee133 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:962098cc-2d84-4723-a296-b110f1fd659e (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c2affa00-1d57-4d85-8db3-745191b4714d (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87f53c04-075c-4d09-925a-0faeaa14f3f9 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51008af2-39ac-546c-e063-6294a90a758f (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e23d8a74-b47b-462a-b09c-90bdd58a032e (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ab4c1f36-82fa-40a2-a31a-227875d0f382 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38694974-3dc6-42b5-bdf9-b5354e35330b (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f36f519-c30c-4929-afa0-9844dc531e3f (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2515391e-3a88-4226-92e5-f641c8409fe5 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        D i stribution The apparent volume of distribution of MHD is 49 L.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec033897-21b4-4d08-83de-042783e89251 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50873ef7-3deb-7386-e063-6394a90a9c19 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0f9df3f-280e-4394-8d7e-ad04803b2635 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03bec567-a9c3-4d82-9679-fec5324d0df6 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbea45c2-e166-b557-e053-2995a90a7643 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:95867dcd-fd0e-4570-987b-d35939f7d7d1 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d947e9b1-2a15-4048-bb4e-fe56b6851848 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a18f591b-587e-4769-8ac2-9cfba0b82526 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:188a48ad-c412-416a-b15b-de5f232740a2 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e0f8d9f-7659-4524-8f93-6200314356c8 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8841174a-9f4b-424f-a50d-01478f2aeb29 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:512ab25c-ea79-1e59-e063-6294a90ae9a0 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:255f64ba-7667-48e6-8599-3b598bf6f4e9 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:62dfed1d-4c5b-446d-97b3-bad9c33959ff (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e156339c-f79e-4a20-b9da-f50bea948213 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d3684d55-0564-4849-bdf6-b91f22a3e28c (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ef6a941-a017-40f2-a50a-ab66c43b3347 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3fb47782-3dfc-458c-92a6-493de1207c0e (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ecd5eef-46f4-407f-9b63-ba65adb3eced (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7718f8b-63e2-40b9-b519-e687cfc2cacf (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a2032bcc-2da5-45e5-aa3f-ddbf50909df8 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa610e56-1d1d-11e1-8bc2-0800200c9a66 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c42b2cb2-8b45-488b-bf63-81909a1f06cb (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5048dc87-2d89-434d-be51-4a97b0ce0601 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd8da0e9-d69b-7587-e053-6294a90a33c0 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f15c889-4386-850b-e063-6294a90a8dbf (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1b6a698-f7d9-4adb-9e38-b63e7a85e2b3 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:567c0777-9bc5-45a9-ba25-959dd76d0e05 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b571ee0f-3c2a-4c55-9c2b-e00014e2ec7a (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54fb494e-bce4-442d-954a-757f9851e81e (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:148b90ba-236a-47cc-b171-22dd7f8f8e0a (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        D i stribution The apparent volume of distribution of MHD is 49 L.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23137a89-cbd0-4a5f-8220-f26b7ba54330 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78f196d4-110e-45b1-813a-725f52c1a4eb (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d3c7a3b8-b9a2-4a5f-98b3-0ed02eca3433 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1746d95f-c529-45ba-a520-0c135e8edda8 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1176d5f5-3447-4925-aed8-1a1cb4b5989d (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b9db5c45-8b51-449b-b4af-1a235c08f189 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7be73d22-f87b-4459-a91c-37c1e34db230 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85a9bdee-4d10-4097-ae3d-0bf8d844a11b (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a90cd1f1-5258-4b0e-92fd-c4cebe47772b (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b0bc10f0-7d1b-4adc-bc59-c48dab58ee5a (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9f5d17e4-ca68-48e2-9e87-d3ab1c59aa93 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0abe9478-4084-286d-e063-6294a90a9ba7 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe49a773-562c-4da6-96b7-bba52f4d61e2 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1c713b59-a628-42e6-b166-ae71c3913284 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6d2a6cac-f16b-4e6c-8f75-3afffb0a0f3b (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e74bb389-8426-4ffc-a14b-a5990de6d0d4 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c5c86c8-ab7f-4fcf-bc1b-5a0b1fd0691b (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:62ab716b-f05f-454d-95b3-1a382cdf7226 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:636fc847-b3d2-4255-a959-d75499fdb198 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ffc8d10c-0049-4fe5-beb8-79cc6a197ede (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:867eaf99-3e31-4f75-bfae-2898804d956d (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a14b5756-4fd1-4ba7-bc23-e1fa9212a148 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:70798ca9-0eda-49c0-8a7c-b775b6ae3d69 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20d826cd-fa4a-4570-9e10-9d7d10fb725b (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:682a1210-b26e-426e-8ffe-d25d91bdd608 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:433d9d03-a36e-42c6-8e4d-f333ed60e45a (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d5ba8a3-d1ea-4d5b-aafd-3a7ba2d4746c (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47b92168-6832-1e0b-e063-6394a90a079a (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:244f9a68-5ab4-46b8-a01f-538572fd3c5f (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e46d4654-76bc-4c33-ac2b-e89ae11b7697 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fcf5044a-8cfd-47d5-9f47-8f6674843c24 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1d54def-057d-4608-bc8f-1d967ac3ec91 (opens source in a new tab)

        Oxcarbazepine label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution of MHD is 49 L.

  8. Projected row 1148

    Medicine slug
    oxybutynin
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    6
    Source count
    5
    Agreement rate
    1
    Recorded readings

    1. 193 L

      Numeric value
      193
      Unit
      L
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c042bf06-79a3-4dc7-ae05-3ef3cfae9d44 (opens source in a new tab)

        Oxybutynin label

        Version not recorded · Effective date not recorded

        The volume of distribution is 193 L after intravenous administration of 5 mg oxybutynin chloride.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f95920c-5dc2-44e4-b61d-b2c5e05390ba (opens source in a new tab)

        Oxybutynin label

        Version not recorded · Effective date not recorded

        The volume of distribution is 193 L after intravenous administration of 5 mg oxybutynin chloride.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20dee37f-1412-44ed-9e8b-f4379ce23eb0 (opens source in a new tab)

        Oxybutynin label

        Version not recorded · Effective date not recorded

        The volume of distribution was estimated to be 193 L after intravenous administration of 5 mg oxybutynin chloride.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed10f0c9-23d6-4ded-b17f-ed474632a965 (opens source in a new tab)

        Oxybutynin label

        Version not recorded · Effective date not recorded

        The volume of distribution is 193 L after intravenous administration of 5 mg oxybutynin chloride.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec4fd95f-16dc-4acf-b560-b67b7aaef08b (opens source in a new tab)

        Oxybutynin label

        Version not recorded · Effective date not recorded

        The volume of distribution is 193 L after intravenous administration of 5 mg oxybutynin chloride.

  9. Projected row 1149

    Medicine slug
    oxycodone
    Compared field
    bioavailability
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    85
    Source count
    13
    Agreement rate
    0.538462
    Recorded readings

    1. 60%

      Numeric value
      60
      Unit
      %
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6d249bc5-79c4-4c42-a71b-d667c75163db (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Absorption The oral bioavailability of oxycodone is 60% to 87%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cff0c64a-63f5-4b3c-909a-cdecf6755cbe (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Absorption The oral bioavailability of oxycodone is 60% to 87%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bfdfe235-d717-4855-a3c8-a13d26dadede (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        The oral bioavailability of oxycodone is 60% to 87%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a6b0659-6816-4f44-81bd-9bac4da5380d (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Absorption: The oral bioavailability of oxycodone is 60% to 87%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c2c57ae7-86b9-47bb-a31b-ed1c4327ce7f (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        The oral bioavailability of oxycodone is 60% to 87%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:685f409f-946f-4b7e-8130-5ad7b92a5e7a (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Absorption The oral bioavailability of oxycodone is 60% to 87%.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e4fbf3fd-8755-4699-9a61-ba7fada0f93f (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Absorption The oral bioavailability of oxycodone is 60% to 87%.

    2. 60 - 87%

      Numeric value
      60
      Unit
      %
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:73b063b5-24b7-40bf-bc2a-c0e1bfaf61d1 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Absorption The oral bioavailability of oxycodone is 60 - 87%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e84ea009-3cab-4721-bd21-1123eccce515 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Absorption The oral bioavailability of oxycodone is 60 to 87%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:819ed9fc-0a21-4ed0-9080-91912c5f8ce2 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Absorption The oral bioavailability of oxycodone is 60 to 87%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8e87c66-f872-4e1d-9ade-ef11490af63b (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Absorption The oral bioavailability of oxycodone is 60 - 87%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2e52a0e-a80b-4225-b034-37a62f839d92 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Absorption The oral bioavailability of oxycodone is 60 to 87%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0079cc8-3642-47f0-9d14-28fd8f212c21 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Absorption The oral bioavailability of oxycodone is 60 to 87%.

  10. Projected row 1150

    Medicine slug
    oxycodone
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    85
    Source count
    26
    Agreement rate
    0.5
    Recorded readings

    1. 4 hours

      Numeric value
      4
      Unit
      hours
      Source records
      13

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 13 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5df92fed-6194-4905-9ef2-9eed0d2e8086 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3745020d-df8c-7209-e063-6394a90aabd7 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6869fec9-1837-4221-afd8-5cc6fadd025d (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3eddd18b-695a-4e53-a76c-f6779515b918 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5451bcaa-0aca-4581-bcea-2f9c2a33b260 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b3fa92e-8351-4401-860d-4bba8a7155e6 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:69410bf3-0d3a-41f9-b10a-c4ee3770f728 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2e52a0e-a80b-4225-b034-37a62f839d92 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of Oxycodone was approximately 4 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c801963d-f54d-4ed5-82c4-8b278528d3dc (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:391701e5-2035-43fa-91ce-d27a1af19492 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de96e2be-66d9-4bcb-a133-221ad32e09f1 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:338b5391-e5f7-40a2-8b15-57f47cbc4813 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        The total plasma clearance was 0.8 L/min for adults.Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:744f5d1c-7427-492c-8994-c8e817793e53 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        The total plasma clearance was 0.8 L/min for adults.Apparent elimination half-life of oxycodone following the administration of oxycodone is approximately 4 hours.

    2. 3.5 to 4 hours

      Numeric value
      3.5
      Unit
      hours
      Source records
      11

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 11 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b2510d72-bf63-4c9d-ac5e-7bacd993fa10 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone HCl was 3.5 to 4 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:094b64b3-cd32-4de5-afb6-ea00d9caad74 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone HCl was 3.5 to 4 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4e9e945d-5ffc-48de-99fa-3fb36c5bc2b9 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone HCl was 3.5 to 4 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f849c7cc-fa85-47eb-be30-1be137913bf9 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone HCl was 3.5 to 4 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b6db42b-9821-4aa6-8566-297037d84079 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone HCl was 3.5 to 4 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc7fdf7e-ad4e-4a04-b35c-2233cc7e5f15 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone HCl was 3.5 to 4 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d248ceba-9492-4348-aa07-31c9c73a3620 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone HCl was 3.5 to 4 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:525001a6-68d8-7ef7-e063-6294a90abc5f (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone HCl was 3.5 to 4 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a8157d3-ba20-4abf-b0d4-6ad141b31d63 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of ROXICODONE was 3.5 to 4 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9da42120-0214-45cb-bb98-9a7739e72d43 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone HCl was 3.5 to 4 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:232d44d2-3924-4d35-873c-d2aef75e9a41 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of oxycodone HCl was 3.5 to 4 hours.

    3. 3-4 hours

      Numeric value
      3
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cff0c64a-63f5-4b3c-909a-cdecf6755cbe (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Thereafter, oxycodone concentrations fall with an average terminal half-life ranging between 3-4 hours.

    4. 3.8 to 4.3 hours

      Numeric value
      3.8
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:72398542-8e0a-47b2-afeb-9ca5a1f15083 (opens source in a new tab)

        Oxycodone label

        Version not recorded · Effective date not recorded

        Apparent elimination half-life of oxycodone following the administration of ROXYBOND was 3.8 to 4.3 hours.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=1140

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy